# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Data to be featured in Presidential Symposium at ESMOSignatera™ changes the paradigm by expanding the adjuvant decision window,...
Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and maintains $200 price target.
Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers